dehydroepiandrosterone has been researched along with Pain, Chronic in 7 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| " If an association was found, we further explored dose-response relationships by the number of pain locations and the degree of pain interference." | 5.62 | Blood Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate as Pathophysiological Correlates of Chronic Pain: Analyses Using a National Sample of Midlife Adults in the United States. ( Chapman, BP; Li, R; Smith, SM, 2021) |
| "Many dysfunctional and chronic pain conditions overlap." | 2.53 | Dysfunctional stress responses in chronic pain. ( Dutheil, F; Picard, P; Woda, A, 2016) |
| " If an association was found, we further explored dose-response relationships by the number of pain locations and the degree of pain interference." | 1.62 | Blood Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate as Pathophysiological Correlates of Chronic Pain: Analyses Using a National Sample of Midlife Adults in the United States. ( Chapman, BP; Li, R; Smith, SM, 2021) |
| "Patients with temporomandibular disorders (TMD) commonly experience myofascial and joint pain, pain-related disability, and other pain conditions including depression." | 1.43 | Association of pain intensity, pain-related disability, and depression with hypothalamus-pituitary-adrenal axis function in female patients with chronic temporomandibular disorders. ( Ahn, RS; Jo, KB; Lee, IG; Lee, SC; Lee, YJ; Park, JY, 2016) |
| " Understandably, physicians might not believe patients who claim that a standard opioid dosage is an ineffective treatment." | 1.42 | Hormone abnormalities in patients with severe and chronic pain who fail standard treatments. ( Tennant, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Haack, M | 1 |
| Engert, LC | 1 |
| Besedovsky, L | 1 |
| Goldstein, MR | 1 |
| Devine, JK | 1 |
| Dang, R | 1 |
| Olia, K | 1 |
| Molina, V | 1 |
| Bertisch, SM | 1 |
| Sethna, N | 1 |
| Simpson, N | 1 |
| Li, R | 1 |
| Chapman, BP | 1 |
| Smith, SM | 1 |
| Tennant, F | 1 |
| Jo, KB | 1 |
| Lee, YJ | 1 |
| Lee, IG | 1 |
| Lee, SC | 1 |
| Park, JY | 1 |
| Ahn, RS | 1 |
| Woda, A | 1 |
| Picard, P | 1 |
| Dutheil, F | 1 |
| Rendina, DN | 1 |
| Ryff, CD | 1 |
| Coe, CL | 1 |
| Aloisi, AM | 1 |
| Buonocore, M | 1 |
| Merlo, L | 1 |
| Galandra, C | 1 |
| Sotgiu, A | 1 |
| Bacchella, L | 1 |
| Ungaretti, M | 1 |
| Demartini, L | 1 |
| Bonezzi, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relationship Between Central Sensitization and Alteration of Circulating Neurosteroid Following Bilateral Total Knee Arthroplasty[NCT03298711] | 69 participants (Actual) | Observational | 2017-11-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dehydroepiandrosterone and Pain, Chronic
| Article | Year |
|---|---|
Dysfunctional stress responses in chronic pain.
Topics: Chronic Pain; Cushing Syndrome; Cytokines; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; H | 2016 |
6 other studies available for dehydroepiandrosterone and Pain, Chronic
| Article | Year |
|---|---|
Alterations of pain pathways by experimental sleep disturbances in humans: central pain-inhibitory, cyclooxygenase, and endocannabinoid pathways.
Topics: Chronic Disease; Chronic Pain; Cyclooxygenase 2; Dehydroepiandrosterone; Endocannabinoids; Female; H | 2023 |
Blood Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate as Pathophysiological Correlates of Chronic Pain: Analyses Using a National Sample of Midlife Adults in the United States.
Topics: Adult; Aged; Aged, 80 and over; Chronic Pain; Cohort Studies; Cross-Sectional Studies; Dehydroepiand | 2021 |
Hormone abnormalities in patients with severe and chronic pain who fail standard treatments.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Biomarkers; Chronic Pain; Dehydroepiandrosterone; Female; | 2015 |
Association of pain intensity, pain-related disability, and depression with hypothalamus-pituitary-adrenal axis function in female patients with chronic temporomandibular disorders.
Topics: Adult; Chronic Pain; Circadian Rhythm; Comorbidity; Dehydroepiandrosterone; Depression; Depressive D | 2016 |
Precipitous Dehydroepiandrosterone Declines Reflect Decreased Physical Vitality and Function.
Topics: Adult; Aged; Aged, 80 and over; Aging; Biomarkers; Chronic Disease; Chronic Pain; Dehydroepiandroste | 2017 |
Chronic pain therapy and hypothalamic-pituitary-adrenal axis impairment.
Topics: Adrenocorticotropic Hormone; Adult; Age Factors; Aged; Analgesics; Case-Control Studies; Chronic Pai | 2011 |